Last updated on November 2019

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Locally Advanced or Metastatic Solid Tumor
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Male or female patients 18 years of age at the time of informed consent.
  2. Part 1 Histologically confirmed diagnosis of a locally advanced or metastatic solid tumor for which paclitaxel is considered appropriate treatment.
  3. Part 2
    • Triple-negative and Stage IV inflammatory breast cancer.
    • Recurrent ovarian cancer.
    • Recurrent, metastatic or high-risk endometrial cancer.
  4. ECOG PS of 2.
  5. Able to provide an archival tumor tissue sample
  6. Adequate organ function and bone marrow reserve
  7. If a female of childbearing potential, must have a negative pregnancy test prior to enrollment.
  8. Patient must provide signed consent to participate in the study and is willing to comply with study-specific procedures.

Exclusion Criteria:

  1. Received prior anticancer or other investigational therapy within 28 days or 5 the half-life prior to the first dose.
  2. Not recovered from prior-treatment toxicities to Grade 1.
  3. Peripheral neuropathy of any etiology >Grade 1.
  4. Concurrent malignancy.
  5. Known active CNS metastases.
  6. Use of systemic corticosteroids.
  7. Known retinal neovascularization, macular edema or macular degeneration.
  8. History or presence of clinically relevant cardiovascular abnormalities.
  9. QTcF >450 ms in males or >470 ms in females.
  10. Left ventricular ejection fraction (LVEF) <50% at screening.
  11. Arterial thrombotic or embolic events.
  12. Venous thrombotic event.
  13. Active infection Grade 3.
  14. HIV or HCV infection only if taking medications excluded per protocol, active HBV, or active HCV infection.
  15. Use of proton pump inhibitors.
  16. If female, the patient is pregnant or lactating.
  17. Major surgery 4 weeks prior to the first dose of study drug
  18. Malabsorption syndrome or other illness which could affect oral absorption.
  19. Known allergy or hypersensitivity to any component of rebastinib or any of its excipients.
  20. Any other clinically significant comorbidities

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.